First Nebraska Trust’s TG Therapeutics TGTX Stock Holding History

First Nebraska Trust’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$233K	Hold	7,000	–	–	0.02%	204
2025 Q4	$209K	Hold	7,000	–	–	0.02%	214
2025 Q3	$253K	Sell	7,000 -3,000	-30%	-$98.8K	0.02%	183
2025 Q2	$360K	Hold	10,000	–	–	0.03%	145
2025 Q1	$394K	Hold	10,000	–	–	0.04%	139
2024 Q4	$301K	Hold	10,000	–	–	0.03%	160
2024 Q3	$234K	Hold	10,000	–	–	0.02%	186
2024 Q2	$178K	Hold	10,000	–	–	0.02%	192
2024 Q1	$152K	Buy	+10,000	New	+$159K	0.02%	190

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

First Nebraska Trust's TGTX Position: Q1 2026 in Review

First Nebraska Trust held its TG Therapeutics (TGTX) position steady in Q1 2026 at 7,000 shares worth $233K. The position accounts for 0.02% of the portfolio, ranked #204.

First Nebraska Trust first reported a position in TGTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $394K in Q1 2025. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

First Nebraska Trust held 7,000 shares of TG Therapeutics worth $233K as of Q1 2026.
First Nebraska Trust left its TG Therapeutics share count unchanged in Q1 2026.
TG Therapeutics made up 0.02% of First Nebraska Trust's portfolio in Q1 2026, its #204 holding.
First Nebraska Trust first reported a position in TG Therapeutics in Q1 2024 and has held it in 9 quarters since.
First Nebraska Trust's TG Therapeutics position peaked at $394K in Q1 2025.
363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on First Nebraska Trust's 13F filing for Q1 2026, filed 1 Jun 2026.